Skip to content

Thursday, August 27, 2026

Latest:

Loss of NF1 drives ER+ breast cancer metastasis on two fronts
Growing Up Baylor: Dr. Ida Orengo
What at-home skin care devices are worth it?
A novel intervention to potentially improve the outcome of children with malnutrition
Colic: Symptoms and relief

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

TopBP1

CS18: a new drug that can potentially overcome cancer drug resistance

August 13, 2026 Breast Cancer, Cancer, CS18, osimertinib, PARP inhibitors, Research, therapy resistance, TopBP1

CS18 is a candidate for further development as a drug that could become part of combination treatments to prevent or overcome cancer drug resistance.

5D4 disrupts several molecular pathways, including MYC, that lead to cancer growth

October 26, 2023 5D4, Breast Cancer, cancer inhibitor, MYC, ovarian cancer, PARP inhibitor, Research, TopBP1

The findings strongly support the potential use of TopBP1 inhibitors as a targeted cancer therapy.

From the Labs: Image of the Month

From the Labs: Tau travels between neurons

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951